SCHEMBL12379027

SCHEMBL12379027

Cc1cc(S(N)(=O)=O)ccc1NC(=O)CSc1nnc(C)n1-c1ccc(C)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.50
EGFR P00533 2/20 0.49
ERBB2 P04626 2/20 0.49
CCR5 P51681 1/20 0.48
ALDH1A1 P00352 4/20 0.47
USP2 O75604 1/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
GAA P10253 1/20 0.45
HTT P42858 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12379029 0.92 HTT (0.49) KDREGFRERBB2ALDH1A1USP2
SCHEMBL249360 0.90 KDR (0.48) KDREGFRERBB2ALDH1A1USP2
SCHEMBL254195 0.89 KDR (0.47) KDREGFRERBB2ALDH1A1CA12
SCHEMBL14026837 0.85 KMT2A (0.45) KDREGFRERBB2CCR5ALDH1A1
SCHEMBL13090729 0.84 HTT (0.47) KDREGFRERBB2ALDH1A1USP2
SCHEMBL1563220 0.84 KDR (0.47) KDREGFRERBB2ALDH1A1USP2
SCHEMBL250123 0.83 HPGD (0.48) KDREGFRERBB2ALDH1A1USP2
SCHEMBL1563417 0.82 KMT2A (0.54) ALDH1A1USP2KMT2AMAPTGAA
SCHEMBL248407 0.82 HPGD (0.49) KDREGFRERBB2ALDH1A1CA12
SCHEMBL249261 0.81 SLC22A12 (0.66) KDREGFRERBB2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003681-B2 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester ARDEA BIOSCIENCES, INC. (US) 2011-08-23 US disclosed
US-7947721-B2 able to inhibit various mutated RTs, including K103N, Y181C and Y188L Ardes Biosciences Inc. (US) 2011-05-24 US disclosed
US-20100267724-A2 S-TRIAZOLE ALPHA-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE ARDEA BIOSCIENCES, INC. (US) 2010-10-21 US disclosed
US-20100081827-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER ARDEA BIOSCIENCES, INC. (US) 2010-04-01 US disclosed
US-20100069645-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER ARDEA BIOSCIENCES, INC. 2010-03-18 US disclosed
US-20080176850-A1 S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase ARDEA BIOSCIENCES, INC. 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069645-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER GRHPR, POLR2H, ME2 KDR 2465/4885EGFR 2891/4885ERBB2 1458/4885
US-20100267724-A2 S-TRIAZOLE ALPHA-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE SPR, POLR2H, QTRT1 KDR 3049/4885EGFR 3926/4885ERBB2 2736/4885
US-20080176850-A1 S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase SPR, POLR2H, QTRT1 KDR 3392/4885EGFR 3851/4885ERBB2 2714/4885
US-20100081827-A1 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER GRHPR, POLR2H, DECR1 KDR 2627/4885EGFR 2968/4885ERBB2 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.